An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Sarilumab (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; Hypoxaemia; Respiratory insufficiency
Focus Pharmacodynamics; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

26 Feb 2022 Results published in the Clinical Infectious Diseases
08 Sep 2021 Results of this post-hoc analyses published in the Journal of Infectious Diseases
16 Jul 2020 Planned End Date changed from 20 Jul 2021 to 31 Aug 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com